January 25, 2008
To Whom It May Concern
KYORIN Co., Ltd.
5, Kanda Surugadai 2-chome,Chiyoda-ku, Tokyo
Securities Code: 4569; TSE 1st Section

KIPRES® RECEIVED APPROVALS FOR ADDITIONAL INDICATIONTO RELIEVE SYMPTOMS OF ALLERGIC RHINITISKYORIN Co., Ltd. announced today that its wholly owned subsidiary, KYORIN Pharmaceutical Co.,
Ltd. (Headquarter: Tokyo, President: Ikuo Ogihara) received today (i) approval of "Kipres® Tablets
10mg" (INN: montelukast sodium), leukotriene receptor antagonist and currently being marketed for thetreatment of bronchial asthma, for an additional indication to relieve symptoms of allergic rhinitis in
adults and (ii) marketing approval of new formulation "Kipres® Tablets 5mg" only for relief of symptomsof allergic rhinitis in adults.
Montelukast sodium has been developed by Merck & Co., Inc., Whitehouse Station, N.J., U.S.A.,
and KYORIN Pharmaceutical has been contributing to the asthma treatment through marketing products
containing that compound as "Kipres® Tablets 10mg" for adults and "Kipres® Chewable Tablets 5mg" forpediatric patients aged 6 years and older since August 2001, and as "Kipres® Oral Granules 4mg" forpediatric patients aged 1 year and older but under 6 years since October 2007.
It is known that leukotriene is a major mediator in the pathologic condition of allergic rhinitis as wellas bronchial asthma, and Merck & Co., Inc. had developed the montelukast sodium as allergic rhinitis
therapeutic drug since its mechanism of action could have potential to improve symptoms of not only
bronchial asthma but also allergic rhinitis. Montelukast sodium is to date approved for relief ofsymptoms of seasonal allergic rhinitis in fifty countries and of perennial allergic rhinitis in thirteen
countries, and has a wealth of usage experience overseas. Further, domestic clinical trials in Japan withmontelukast sodium showed its beneficial effects on three major symptoms of allergic rhinitis; stuffy nose,runny nose and sneezing, by administering it once a day before bedtime.
The profile of "Kipres® Tablets 10mg" and "Kipres® Tablets 5mg" is as follows:i) Improve three major symptoms of allergic rhinitis (stuffy nose, runny nose and sneezing) byadministering them once a day before bedtime.
ii) Long-term study in the patients with perennial allergic rhinitis showed durability of response fortwelve weeks without waning.
iii) Have an onset of action from the first dosing day.
KYORIN Pharmaceutical has been pursuing Franchise Customers Strategy under which the company
has been concentrating its marketing resources on the fields of respiratory, ear nose throat (ENT), andurology. The company will continue to make efforts to further contribute to asthma and allergic rhinitis
treatments through aiming to immediately penetrate Kipres into the markets of respiratory and ENT.
###Contacts:
Management Planning Department
KYORIN Co., Ltd.
TEL: 3-3293-3414

<Products Profile>
1. Brand Name
2. Nonproprietary Name
3. Indications
4. Dosage and Administration

Kipres® Tablets 5mg
Kipres® Tablets 10mg
Montelukast Sodium
Bronchial Asthma, Allergic Rhinitis< Bronchial Asthma >Recommended dosage for adults is usually 10mg as montelukast
orally administered once daily before bedtime.
< Allergic Rhinitis >Recommended dosage for adults is usually 5-10mg as montelukastorally administered once daily before bedtime.
5. NHI Price
JPY 287.10 per tablet
Not yet listed
6. Packaging
PTP 28, 100, 140, and 420 tablets PTP 28, 100, and 140 tablets* NHI price listing for Kipres Tablets 5mg will be expected in April 2008.

Reference
1. Brand Name
2. Indications
3. Dosage and Administration

4. NHI Price
5. Packaging

Kipres® Oral Granules 4mg
Bronchial Asthma
Recommended dosage forpediatric patients aged 1 year orolder but under 6 years is usually
4mg (1 packet) as montelukast
orally administered once dailybefore bedtime.
JPY 268.80 per packet
Aluminum Packet 28, 100, and140 packets

Kipres® Chewable 5mg
Recommended dosage forpediatric patients aged 6 years orolder is usually 5mg asmontelukast orally administeredonce daily before bedtime.
JPY 268.80 per tablet
PTP 28 and 100 tablets